Food and Drug Administration Center for Biologics Evaluation and Research

Vaccines and Related Biological Products Advisory Committee Meeting January 25, 2007

Doubletree Hotel, 8120 Wisconsin Ave., Bethesda, MD DRAFT AGENDA

8:00 a.m.	Call to Order Presentation of Appreciation Plaques to To retiring members	Ruth A. Karron, M.D., Chair Norman Baylor, Ph.D., FDA	
8:05	Administrative Matters	Christine Walsh R.N., FDA	
<u>Session 1 – Open Committee Discussion – Safety and Immunogenicity of Diphtheria</u> <u>& Tetanus Toxoids & Acellular Pertussis Adsorbed , Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine Combined (DTaP-IPV/Hib), Pentacel TM, manufactured by Sanofi Pasteur Limited</u>			
8:10 a.m.	Introduction/Background/DTaP-IPV/Hib Presentation of Questions	Theresa Finn, Ph.D., FDA	
8:15	DTaP-IPV/Hib / (Pentacel TM)	Luc Kuykens, M.D., MPH, SP Michael Decker, M.D., MPH, SP Scott Halperin, M.D., SP David Greenberg, M.D., SP	
9:30	Clarifications/Questions		
9:45	BREAK		
10:00	FDA Presentations	Karen Farizo, M.D., FDA Theresa Finn, Ph.D., FDA	
11:05	Clarifications/Questions	Theresa Film, Fil.D., FDA	
11:15	Open Public Hearing		
11:45	Committee Discussion and Recommendations		
1:00 p.m.	Lunch		
Session II – Open Committee Discussion - Overview Office Vaccines Research And Review, CBER			
2:00	Overview of CBER Research Programs	Kathryn Carbone, MD, FDA	
2:15	Clarifications/Questions		
2:20	Overview Office of Vaccines Research And Review	Norman Baylor, Ph.D, FDA	

2:35	Clarifications/Questions	
2:40	Office of Vaccines Research and Review Research Program	Michael Brennan, Ph.D., FDA
2:55	Clarifications/Questions	
3:00	Break	
3:15	Overview Division of Viral Products	Jerry Weir, Ph.D., FDA
3:30	Clarifications/Questions	
3:35	Overview Division of Bacterial Parasitic And Allergenic Products	Richard Walker, Ph.D., FDA
3:50	Clarifications/Questions	
3:55	Open Public Hearing	
4:25	Session III - Closed Session	
5:00	Adjourn Meeting	